Loading patent…
OwnerYoram Richter, Elazer Edelman +2inventors
InventorsYoram Richter, Elazer Edelman, Gershon Golomb, Haim Danenberg
Estimating the term…
The present invention relates to methods and compositions designed for the prevention, reduction, treatment or management of ischemia-reperfusion injury. The methods of the invention comprise the administration of an effective amount of a therapeutic formulation containing one or more active compounds in a formulation which specifically decreases or inhibits the activity of and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and/or monocytes. In preferred embodiments, the active compound is a bisphosphonate. The invention also provides pharmaceutical compositions of therapeutic formulations for administration to subjects currently suffering from, having recently suffered, or at risk of suffering from an ischemia-reperfusion injury.
A method of treating an ischemia-reperfusion injury comprising administering to a patient in need thereof an effective amount of a formulation comprising an encapsulated active compound, wherein the formulation reduces a zone of infarct, thereby minimizing the damage of the ischemia-reperfusion injury.
A method of treating an ischemia-reperfusion injury comprising administering to a patient in need thereof an effective amount of a formulation comprising an embedded active compound, wherein the formulation reduces a zone of infarct, thereby minimizing the damage of the ischemia-reperfusion injury.
A method of treating an ischemia-reperfusion injury comprising administering to a patient in need thereof an effective amount of a formulation comprising a particulate active compound, wherein the formulation reduces a zone of infarct, thereby minimizing the damage of the ischemia-reperfusion injury.
A method of treating an ischemia-reperfusion injury followed by tissue necrosis comprising administering to a patient in need thereof an effective amount of a formulation comprising an encapsulated bisphosphonate, thereby minimizing damage resulting from the tissue necrosis.
A method of treating an ischemia-reperfusion injury followed by tissue necrosis comprising administering to a patient in need thereof an effective amount of a formulation comprising an embedded bisphosphonate, thereby minimizing damage resulting from the tissue necrosis.
A method of treating an ischemia-reperfusion injury followed by tissue necrosis comprising administering to a patient in need thereof an effective amount of a formulation comprising a particulate bisphosphonate, thereby minimizing damage resulting from the tissue necrosis.
A method of reducing the zone of infarct following an ischemia-reperfusion injury comprising administering to an individual in need thereof an effective amount of a formulation comprising an encapsulated bisphosphonate.
A method of reducing the zone of infarct following an ischemia-reperfusion injury comprising administering to an individual in need thereof an effective amount of a formulation comprising an embedded bisphosphonate.
A method of reducing the zone of infarct following an ischemia-reperfusion injury comprising administering to an individual in need thereof an effective amount of a formulation comprising a particulate bisphosphonate.
Dependencies are inferred from the claim text.